MX2015016875A - Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. - Google Patents
Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.Info
- Publication number
- MX2015016875A MX2015016875A MX2015016875A MX2015016875A MX2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A MX 2015016875 A MX2015016875 A MX 2015016875A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- glp
- peptides
- side chains
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
Abstract
La presente invención se relaciona con derivados de péptidos similares a GLP-1 que son análogos extendidos C-terminalmente de GLP-1 nativo. Los derivados comprenden dos cadenas laterales, una en una posición que corresponde a la posición 42, y una posición que corresponde a la posición 18, 23, 27, 31, 36 ó 38, en donde ambas posiciones son cuando se comparan con GLP-1(7-37). Las cadenas laterales comprenden el radical de prolongación diácido C19, C20 o C22 y opcionalmente un enlazador. La invención también se relaciona con productos intermediarios en la forma de nuevos análogos de GLP-1 incorporados en los derivados de la invención, así como las composiciones farmacéuticas y usos médicos de los derivados. Los derivados tienen viudas medias muy largas, mientras que mantienen una potencia satisfactoria, lo que los hace potencialmente apropiados para la administración una vez al mes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13175094 | 2013-07-04 | ||
US201361845646P | 2013-07-12 | 2013-07-12 | |
PCT/EP2014/064033 WO2015000942A1 (en) | 2013-07-04 | 2014-07-02 | Derivatives of glp-1 like peptides, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015016875A true MX2015016875A (es) | 2016-04-07 |
Family
ID=48703344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015016875A MX2015016875A (es) | 2013-07-04 | 2014-07-02 | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US9498534B2 (es) |
EP (1) | EP3016975B1 (es) |
JP (2) | JP6139712B2 (es) |
KR (1) | KR20160029079A (es) |
CN (1) | CN105377884B (es) |
AR (1) | AR096789A1 (es) |
AU (1) | AU2014286234A1 (es) |
BR (1) | BR112015032875A2 (es) |
CA (1) | CA2916311A1 (es) |
MX (1) | MX2015016875A (es) |
WO (1) | WO2015000942A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3010546B1 (en) | 2013-06-20 | 2017-08-09 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
KR20160029079A (ko) * | 2013-07-04 | 2016-03-14 | 노보 노르디스크 에이/에스 | Glp-1 유사 펩티드의 유도체 및 그것의 사용 |
JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー/エス | Glp−1誘導体及びその使用 |
WO2016097108A1 (en) | 2014-12-17 | 2016-06-23 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
WO2016197009A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
US10946074B2 (en) | 2016-03-03 | 2021-03-16 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
EP3534962B1 (en) | 2016-11-07 | 2020-08-19 | Novo Nordisk A/S | Dchbs-active esters of peg compounds and their use |
WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
CN108976147B (zh) * | 2017-05-31 | 2021-02-12 | 首都医科大学 | 氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸,其合成,活性和应用 |
CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
EP3655427A1 (en) | 2017-07-19 | 2020-05-27 | Novo Nordisk A/S | Bifunctional compounds |
PL3474820T3 (pl) | 2017-08-24 | 2024-05-13 | Novo Nordisk A/S | Kompozycje glp-1 i ich zastosowania |
JP7359358B2 (ja) * | 2017-11-30 | 2023-10-11 | グリアファーム エスエー | 神経疾患の予防及び治療に使用するためのポリケチド化合物及びその誘導体 |
PL4122954T3 (pl) | 2018-04-05 | 2024-08-12 | Sun Pharmaceutical Industries Limited | Nowe analogi GLP-1 |
CN110386974B (zh) * | 2018-04-19 | 2022-12-09 | 杭州先为达生物科技有限公司 | Glp-1衍生物及其治疗用途 |
CN113214382B (zh) * | 2018-04-19 | 2024-01-19 | 杭州先为达生物科技股份有限公司 | 酰化的glp-1衍生物 |
WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
KR102390531B1 (ko) * | 2018-07-12 | 2022-04-25 | 미쓰비시덴키 가부시키가이샤 | 반도체 장치 |
CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
TW202140063A (zh) | 2020-02-18 | 2021-11-01 | 丹麥商諾佛 儂迪克股份有限公司 | 醫藥配方 |
EP4222176A4 (en) | 2020-09-30 | 2024-02-28 | Beijing QL Biopharmaceutical Co., Ltd. | POLYPEPTIDE CONJUGATES AND METHODS OF USE |
WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
JP2002512175A (ja) * | 1998-02-27 | 2002-04-23 | ノボ ノルディスク アクティーゼルスカブ | Glp−1類似体の誘導体類 |
IL144989A0 (en) | 1999-03-17 | 2002-06-30 | Novo Nordisk As | Method for acylating peptides and novel acylating agents |
EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
JP2003516322A (ja) | 1999-11-12 | 2003-05-13 | ノボ ノルディスク アクティーゼルスカブ | ベータ細胞変性抑制のためのglp−1アゴニストの使用 |
GB0020551D0 (en) | 2000-08-22 | 2000-10-11 | Birkett David | Sprinkler system |
CA2518336A1 (en) | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
EP1881850B1 (en) | 2005-05-13 | 2010-09-29 | Eli Lilly And Company | Glp-1 pegylated compounds |
JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー/エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
ES2532116T3 (es) | 2007-09-05 | 2015-03-24 | Novo Nordisk A/S | Péptidos derivados con A-B-C-D y sus usos terapéuticos |
US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
ES2401965T3 (es) | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
CN102791731B (zh) * | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | Glp-1类似物和衍生物 |
EP2637699B1 (en) | 2010-11-09 | 2018-05-16 | Novo Nordisk A/S | Double-acylated glp-1 derivatives with a linker |
HUE031405T2 (en) | 2011-04-12 | 2017-07-28 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
KR20160029079A (ko) * | 2013-07-04 | 2016-03-14 | 노보 노르디스크 에이/에스 | Glp-1 유사 펩티드의 유도체 및 그것의 사용 |
-
2014
- 2014-07-02 KR KR1020167002151A patent/KR20160029079A/ko not_active Application Discontinuation
- 2014-07-02 MX MX2015016875A patent/MX2015016875A/es unknown
- 2014-07-02 AU AU2014286234A patent/AU2014286234A1/en not_active Abandoned
- 2014-07-02 CN CN201480038380.6A patent/CN105377884B/zh active Active
- 2014-07-02 BR BR112015032875A patent/BR112015032875A2/pt not_active Application Discontinuation
- 2014-07-02 EP EP14734816.3A patent/EP3016975B1/en active Active
- 2014-07-02 WO PCT/EP2014/064033 patent/WO2015000942A1/en active Application Filing
- 2014-07-02 JP JP2015563070A patent/JP6139712B2/ja active Active
- 2014-07-02 AR ARP140102467A patent/AR096789A1/es unknown
- 2014-07-02 US US14/322,077 patent/US9498534B2/en active Active
- 2014-07-02 CA CA2916311A patent/CA2916311A1/en not_active Withdrawn
-
2016
- 2016-09-28 US US15/278,501 patent/US10010614B2/en active Active
-
2017
- 2017-02-09 JP JP2017022249A patent/JP6687557B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN105377884B (zh) | 2021-07-20 |
EP3016975B1 (en) | 2019-01-16 |
US10010614B2 (en) | 2018-07-03 |
CN105377884A (zh) | 2016-03-02 |
JP2016528163A (ja) | 2016-09-15 |
AR096789A1 (es) | 2016-02-03 |
CA2916311A1 (en) | 2015-01-08 |
EP3016975A1 (en) | 2016-05-11 |
WO2015000942A1 (en) | 2015-01-08 |
US9498534B2 (en) | 2016-11-22 |
JP6687557B2 (ja) | 2020-04-22 |
US20150011462A1 (en) | 2015-01-08 |
BR112015032875A2 (pt) | 2017-11-07 |
KR20160029079A (ko) | 2016-03-14 |
JP6139712B2 (ja) | 2017-05-31 |
US20170007707A1 (en) | 2017-01-12 |
AU2014286234A1 (en) | 2015-12-17 |
JP2017105819A (ja) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015016875A (es) | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. | |
MX2015016564A (es) | Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos. | |
PH12019501056A1 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
PH12014501924A1 (en) | Xten conjugate compositions and methods of making same | |
MX2019000566A (es) | Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. | |
ZA201805336B (en) | Amanitin conjugates | |
PH12017502393A1 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
MX369818B (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
MX2017015105A (es) | Compuestos del peptido yy (pyy) selectivos y sus usos. | |
MX2016016063A (es) | Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. | |
MX2017008215A (es) | Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina. | |
MX2020009857A (es) | Conjugados de interleucina-2 (il-2). | |
MA40030A (fr) | Conjugués peptide-médicament | |
NZ623294A (en) | Stabilized alpha-galactosidase and uses thereof | |
PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
PH12020550105A1 (en) | Long-acting conjugates of glp-2 derivatives | |
PH12017501280B1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
PH12018501351A1 (en) | Cortistatin analogs and uses thereof | |
MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
MX2022006737A (es) | Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. | |
PH12017501205A1 (en) | Glucagon derivatives | |
MX2021007124A (es) | Composicion farmaceutica que incluye insulina y glucagon. | |
EP3888647A4 (en) | EZH1/2 DUAL INHIBITOR CONTAINING PHARMACEUTICAL COMPOSITION FOR USE AS COMBINATION MEDICINAL PRODUCT |